Revenue segments as reported by the company.

Waters

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative expenses

Research and development expenses

Purchased intangibles amortization

Asset impairment

Litigation provision

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Waters Corp. engages in the provision of workflow solutions involving liquid chromatography, mass spectrometry, and thermal analysis. It operates through the Waters and TA (TA Instruments) segments. The Waters segment consists of liquid chromatography instruments, mass spectrometry, and precision chemistry consumable products and services. The TA segment products and services include thermal analysis, rheometry and calorimetry instrument systems, and service sales. The company was founded by James Logan Waters in 1958 and is headquartered in Milford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Waters reports robust Q4 earnings, eyes growth through acquisitions

Waters Corporation's strong performance in Q4 2022 and full-year results, coupled with the Wyatt Technology acquisition, positions the company for continued growth.
Despite challenges in China and FX headwinds, Waters sees opportunities in pricing increases, revenue synergies from acquisitions, and growth in bioanalytical applications.

Waters Corp reports Q1 revenue growth below expectations, eyes biotech

Waters Corporation faces challenges from weaker demand in key sectors but maintains strengths in certain divisions and sustainability efforts. The acquisition of Wyatt Technology presents growth opportunities, with a focus on maintaining pricing strength and capitalizing on ongoing pharma activity.

Waters (WAT) reports robust Q2 growth, eyes Chinese market recovery

Waters Corporation delivered strong Q2 performance with 5% constant currency growth and non-GAAP EPS above expectations, driven by operational excellence and margin expansion.
While challenges persist in the China Pharma market and cautious spending trends impact growth outlook, Waters remains well-positioned for growth above market rates.
The company's strategic strengths in innovation, execution, and margin expansion, coupled with growth opportunities in key segments and regions, position it for continued success.

Waters expands margins amidst China challenges, eyes service growth

Waters Corporation navigated through challenges in China, focusing on margin expansion, cost management, and workforce optimization. Despite headwinds, the company showcased resilience, positive cash flow, and growth opportunities in service attachment rates and e-commerce sales.

Waters faces sales decline in Q4 2023, eyes PFAS market

Waters navigated a challenging Q4 2023 with sales decline and cautious Q1 2024 guidance. Despite China's struggles, the company's operational resilience and focus on sustainability are strengths. Opportunities lie in PFAS testing, e-commerce growth, and large molecule applications.

Waters Corp exceeds EPS guidance, eyes China stimulus for growth

Waters Corporation's Q1 2024 performance was solid, with a focus on margin expansion and innovation. Challenges include sales decline and concerns about revenue targets. Opportunities exist in China's pharma market stabilization and margin progression.

Waters Corporation surpasses Q2 expectations, eyes long-term growth strategies

Waters Corporation delivered strong Q2 results, exceeding expectations with resilient margins.
While facing sales declines, the company showcased operational efficiency and strategic focus.
Guidance reflects caution on ex-China markets but highlights opportunities for growth.
Strategic flexibility in debt management and product innovation position the company for long-term success.

Waters Corporation excels in Q3, eyes growth in key markets

Waters Corporation's strong Q3 performance exceeded expectations, driven by sales growth in key sectors and recurring revenue expansion.
Despite challenges like China sales decline and negative sales growth projections, the company remains optimistic about future opportunities.
With a focus on operational excellence, strategic positioning, and market confidence, Waters is poised for continued success and growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Dr. Pearl S. Huang, President and CEO of Cygnal Therapeutics and venture partner at Flagship Pioneering, has been appointed as a Director of Waters Corporation, effective January 1, 2021. “We are pleased to welcome Pearl to the Waters Board of Directors,” said Dr. Flemming Ornskov, Chairman of the Board. “Pearl is a distinguished executive with significant scientific expertise in the discovery of biologics, smal

Waters Corporation Appoints Pearl S. Huang to Board of Directors

DAEGU, South Korea--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) has formally expanded its long-standing, collaborative relationship with Dr. Sunghwan Kim of Kyungpook National University to further explore the use of Waters' cutting-edge ion mobility spectrometry (IMS) in the investigation of compounds in complex mixtures. Identifying unknown chemicals in complex organic media at the molecular level has become an important but difficult research topic in modern analytical chemistry. For exam

Waters Collaborates with Dr. Sunghwan Kim of Kyungpook National University to Advance Precision Analysis of Complex Chemical Compounds

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) today announced that Sherry Buck will step down as Chief Financial Officer, effective December 31, 2020, in order to pursue another opportunity at a privately held company. Upon her departure, Michael F. Silveira, Vice President and Corporate Controller of Waters, will assume the role of interim Chief Financial Officer. Ms. Buck will work alongside Mr. Silveira in order to facilitate a smooth transition. Waters has been actively wor

Waters Corporation Announces CFO Transition

Waters Corporation occupies a leading position in attractive markets. Historically, the company has outperformed the S&P 500 by a wide margin.

Waters: Analyze This

Extra Space Storage

Freeport-McMoRan

Alphabet

Jazz Pharmaceuticals

Eli Lilly

Medtronic

Parker-Hannifin

Royal Caribbean Cruises

Walmart

It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.

BofA Securities Top 10 US Stock Ideas for the Rest of 2021

Waters Corporation (WAT) CEO Udit Batra on Q3 2020 Results - Earnings Call Transcript

Waters (WAT) delivered earnings and revenue surprises of 13.09% and 8.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Q3 Earnings and Revenues Surpass Estimates

Shares of Waters (NYSE:WAT) moved higher by 0.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 1.41% year over year to $2.16, which beat the estimate of $1.93.

Recap: Waters Q3 Earnings

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced third quarter 2020 sales of $594 million, a 3% increase as reported, compared to sales of $577 million for the third quarter of 2019. Foreign currency translation benefitted sales growth by approximately 1% for the quarter. On a GAAP basis, diluted earnings per share (EPS) for the third quarter of 2020 decreased to $2.03, compared to $2.07 for the third quarter of 2019. On a non-GAAP basis, EPS increased to $2.16, c

Waters Corporation (NYSE: WAT) Reports Third Quarter 2020 Financial Results

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q3 2020 financial results conference call live on Tuesday, October 27th at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters’ website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until November 3rd at midnight eastern time. Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatogr

Waters Corporation Q3 2020 Financial Results Webcast Invitation

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) announced this week at Biotech Week Boston the establishment of Immerse™ Cambridge, a new Waters' research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia, research and industry to accelerate the next generation of scientific advancements. “Immerse Cambridge will house the latest analytical instruments a

Waters Establishes Flagship Innovation and Research Laboratory in Cambridge, MA

BOSTON--(BUSINESS WIRE)-- #DSP--LabMinds, Inc., a pioneer in automation for solution preparation in life sciences, today announced that Waters Corporation (NYSE: WAT), a global leader in specialty measurement in life, food and materials sciences, is outfitting several of its R&D and customer demonstration laboratories with LabMinds’ REVO solution preparation systems.

LabMinds Helps Waters Corporation Enhance Automation and Efficiency of Lab Operations Across Multiple Locations

Waters (WAT) reported earnings 30 days ago. What's next for the stock?

Why Is Waters (WAT) Down 0.2% Since Last Earnings Report?

Waters Corporation (WAT) CEO Chris O'Connell on Q2 2020 Results - Earnings Call Transcript

Waters' (WAT) second-quarter results benefit from cost-cutting strategies. However, coronavirus-led disruptions remained headwinds.

Waters (WAT) Q2 Earnings Beat Estimates, Revenues Down Y/Y

Waters (WAT) delivered earnings and revenue surprises of 37.25% and 0.11%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced second quarter 2020 sales of $520 million, a 13% decrease as reported, compared to sales of $599 million for the second quarter of 2019.

Waters Corporation (NYSE: WAT) Reports Second Quarter 2020 Financial Results

Waters (WAT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Waters (WAT)

The healthcare company's second-quarter results appear better than expected.

Why Waters Stock Is Skyrocketing 12.9% Today

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) will webcast its Q2 2020 financial results conference call live on Tuesday, July 28th at 8:00 a.m. eastern time. To listen to the conference call, connect to Waters’ website, www.waters.com choose “Investors” and click on the Live Webcast. A replay of the webcast will be available until August 4th at midnight eastern time. About Waters Corporation Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has

Waters Corporation Q2 2020 Financial Results Webcast Invitation

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE:WAT) (“Waters” or the “Company”) today announced that Udit Batra, Ph.D. has been named the Company’s President and Chief Executive Officer, effective September 1, 2020. He will also join Waters’ Board of Directors at that time. Dr. Batra succeeds Christopher O’Connell who will remain in his current roles as President and Chief Executive Officer, and as a member of the Board until September 1, 2020. As previously announced, Mr. O’Connell

Waters Corporation Names Udit Batra President and Chief Executive Officer

CVS Health

McKesson

7 Picks For June 2020: 3 Of Them Are Severely Undervalued

American Airlines

Occidental Petroleum

Vornado Realty Trust

Western Union

The stock market has been remarkably resilient this year amid the pandemic and recession.

5 Sickly S&P 500 Stocks to Sell or Avoid

Hidden Stock Market Gems: Waters Corporation

News for Waters Stock (WAT)